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Abstract Noradrenaline effects on voltage-operated calcium 
channels and exocytosis were studied, for the first time, in single 
patch-clamped RINm5F insulin-secreting cells. Noradrenaline, 
despite small and variable inhibition of calcium currents, strongly 
inhibited the increase in membrane capacitance (a measure of 
exocytosis) stimulated by both step depolarizations and the 
calcium ionophore, ionomycin. Noradrenaline similarly inhibited 
KCI- and ionomycin-induced [3H]serotonin release from 
RINmSF cell populations. Noradrenaline ffects were mediated 
by PTX-sensitive G proteins. Noradrenaline inhibitory effects on 
secretion are, therefore, mainly exerted downstream from Ca 2+ 
influx. 
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1. Introduction 
Many hormones and neurotransmitters inhibit release from 
nerve terminals and endocrine cells. Their mechanisms of ac- 
tion include K + channel activation, Ca 2+ channel inhibition, 
as well as effects on the secretory apparatus downstream from 
Ca 2+ elevations [1-6]. 
In relation to the adrenergic inhibition of insulin secretion 
from pancreatic beta cells, both inhibition of voltage-operated 
calcium channels (VOCCs) [7,8] and direct effects on the se- 
cretory apparatus have been demonstrated [9-12]. However, 
while the modulation of calcium channels is mainly studied 
at the single cell level, insulin release is usually studied from 
cell populations, under experimental conditions that differ 
dramatically in terms of membrane potential, ionic composi- 
tion of the buffers and time course. 
Recently, patch-clamp techniques have been described 
which allow the simultaneous measurement of both Ca 2+ cur- 
rents (Ic~) through VOCCs, and the associated changes in cell 
membrane capacitance (ACre) due to exocytosis [13-19]. This 
technique has been applied to many cell types including pan- 
creatic beta cells [20-22] and, recently, the insulinoma cell line 
R INm5F [23]. 
Here we report the first simultaneous characterization of 
adrenergic modulation of VOCCs and exocytosis at the single 
cell level in insulin-secreting R INm5F cells. Our results de- 
monstrate that single R INm5F cells are heterogeneous in their 
responses to the inhibitory neurotransmitter, and that inhibi- 
tion of exocytosis at a point downstream from Ca ~+ influx 
plays a crucial role in the modulation of secretion from these 
cells. We have also confirmed that the noradrenaline-induced 
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inhibition of secretion is mediated by a pertussis toxin (PTX)- 
sensitive G protein. Corroborative vidence that the inhibition 
of ACre represented a reduction in release was obtained by 
measuring [3H]serotonin ([3H]5HT) release from RINm5F 
cell populations. 
2. Materials and methods 
2.1. Cell culture 
The rat insulinoma RINm5F cell line provided by Dr. C.B. Woll- 
heim (University of Geneva, Switzerland) was grown in Roosevelt 
Park Memorial Institute (RPMI)-1640 medium, supplemented with 
10°/0 fetal calf serum, 100 IU/ml penicillin and 100 mg/ml streptomy- 
cin. Cells, incubated at 37°C and at a 5% CO2 concentration i air, 
were trypsinized weekly and replated in either 35 mm tissue culture 
Petri dishes for electrophysiology or in 24 multiwell plates for 
[3H]5HT release xperiments. Cells were used 4-7 days after plating. 
2.2. Electrophysiological recordings 
Ic~ and Cm were measured in the whole-cell patch-clamp configura- 
tion [24], as recently described for RINm5F cells [23]. Briefly, data 
were acquired with an EPC9 amplifier (Instrutech, NY, USA) using 
HEKA software run on a Macintosh Centris 650. Isolated RINm5F 
cells were held at -90 mV and corrected for leak currents by sub- 
tracting four scaled hyperpolarizing pulses to zero-current command 
potentials. Series resistance (Rs) was compensated byat least 50% and 
signals were filtered at 2.9 Hz. 
Cm and R~ were measured automatically by the EPC9 amplifier. 
This time-domain method of capacitance measurement has been 
shown to produce equivalent values of Cm to those obtained with 
the frequency-domain method [16,18]. Cells in which changes in C,, 
were accompanied by either parallel or anti-parallel changes in R~ 
were discarded. Similarly, recordings in which the holding current 
was greater than -100 pA were also removed from the data set. In 
all experiments he reported changes in Cm were determined by aver- 
aging the 4 Cm values before each voltage command and subtracting 
it from the average of the 4 Cm values after the command pulse. The 
temporal resolution of C,~ points was ~ 300 ms, providing 3 data 
points per second. The rate of ionomycin-induced increase in Cm 
was measured in individual cells by linear fit (y=mx+b) of the relevant 
segment of the Cm trace using Igor Pro (Wavemetrics, OR, USA). 
Data were acquired at room temperature (~26°C). Perfusion of the 
cells was achieved by gravity flow using a multi-barrelled pipette sys- 
tem with a flow rate of 0.1 ml/min producing a local exchange at the 
cell within 5 s. 
The extracellular solution contained (in mM): NaCI 125, CaCI2 10, 
MgCI~ 1, 4-aminopyridine (4-AP) 3, tetrodotoxin (TTX) 0.0005, pH 
7.3 with NaOH. Patch pipettes, coated with dental wax to reduce 
stray capacitance, were filled with an intracellular solution containing 
(in mM): Cs-glutamate 125, HEPES 30, tetraethylammonium bro- 
mide (TEA-Br) 20, NaCI 10, MgATP 3, MgCI~ 1, GTP 0.3, cAMP 
0.1, EGTA 0.05, pH 7.3 with CsOH. 
Data are expressed as mean + SEM and statistical significance was 
calculated using Student's t-test. 
2.3. [3H]5HT release 
[3H]5HT release was assayed as recently described [25]. Briefly, 
RINm5F cells were washed three times in phosphate buffered saline 
(PBS). They were then loaded with [3H]5HT creatinine sulfate (100 
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nM) in a Krebs-Ringer-HEPES (KRH) solution containing (in mM): 
NaC1 150, KCI 5, MgSO4 and KH2PO4 1.2, CaC12 2, glucose 6, and 
25 HEPES-NaOH 25 (pH 7.4) and equal amounts of ascorbic acid 
and the monoamine oxidase inhibitor pargyline (0.1 mg/ml). After 1 h 
at 37°C, the cells were washed three times with PBS and returned to 
KRH containing 1~tM of the 5HT reuptake inhibitor Cl-imipramine. 
[aH]5HT release was stimulated with either 50 mM KC1 or 1 ~tM 
ionomycin for 10 rain at 37°C. Cells were then washed three times 
in ice-cold PBS, dissolved in 0.6 ml of 1 M NaOH and transferred to 
plastic vials containing 5 ml of Ultima Gold (Camberra Packard) in 
order to determine the amount of radioactivity remaining associated 
with the cells. Radioactivity was counted in a scintillation beta coun- 
ter (TriCarb 2100 TR, Camberra Packard) with an efficiency of 65%. 
The amount of [3H]5HT release is expressed as percent increase over 
basal. Basal release was measured in parallel 10 min incubations with 
control KRH alone. 
2.4. Materials 
Culture media and supplements were obtained from Seromed (Bio- 
chrom KG, Berlin, Germany) and plastic sterile dishes and multiwell 
plates from Coming (New York, NY, USA). Pargyline, ionomycin, 
ascorbic acid, 4-AP, EGTA, noradrenaline and PTX were purchased 
from Sigma (Milan, Italy). Cl-imipramine was from RBI (Natick, 
MA, USA), [3H]5HT creatinine sulfate (specific activity 15.1 Ci/ 
mmol) from Amersham (Buckinghamshire, UK), TEA-Br from Al- 
drich (Milan, Italy), CsOH from Alfa (Wardhill, MA, USA) and 
TTX from Calbiochem (San Diego, CA, USA). All other salts and 
reagents were purchased from either Merck (Darmstadt, Germany) or 
Sigma. 
3. Results 
Repetitive 200 ms step depolarizations to +10 mV delivered 
every 10 s from a holding potential (Vh) of -90  mV in the 
presence of 10 mM external Ca 2--, produced large AC~ in 
control RINm5F cells (Fig. 1, Ai). The responses of RINm5F 
cells are voltage-dependent and are abolished in the presence 
of external Cd 2+, and therefore represent rue Ca2+-dependent 
exocytosis [23]. The large capacitance steps seen in RINm5F 
cells are probably due to several factors, foremost being that 
RINm5F cell size is variable and the cells used in the present 
study were frequently larger than normal beta cells. Secondly, 
the Ca 2+ concentration of the bath solution was raised to 10 
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Fig. 1. Noradrenergic nhibition of Ica and Cm increases in single RINm5F cells. A: Examples of three consecutive Cm responses to 200 ms. 
depolarizations from a Vh of -90 mV to +10 mV. Responses were elicited every 10 s. The middle response in Ai was in control solution while 
Aii was in the presence of 20 I.tM noradrenaline (NA). The break in Cm sampling occurred during the depolarizing step command when Ica 
shown in Bi and Bii were acquired. Bi and Bii: Three superimposed Ic~ traces corresponding to the Cm data in A are shown. In this particular 
cell, Ica was almost unaffected by NA, while the Cm response was significantly inhibited. C and D: The average secretory response observed 
for three repetitive depolarizations in control solution (C, n = 15) and with exposure to 20 ~tM noradrenaline during the second step (D, n = 17) 
are shown. Data were normalized to the first Cm response for each cell. E: Scatter plot for the noradrenergic inhibition of ACre versus the inhi- 
bition of I¢~ integrals. Both ACre and the integral of Ic~ are normalized to the first response in each cell. 
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mM to ensure robust responses. For the same reason we also 
included 0.1 mM cAMP in the pipette solution. The calcu- 
lated relationship between Ca 2+ influx measured as the inte- 
gral of the current versus the capacitance increase calculated 
for the first step response was 7.44 fF/pC. This value com- 
pares favorably with the value of 8.2 fF/pC reported for 
mouse beta cells [22]. 
Despite a relatively stable Ica (Fig. 1, Bi) there was a grad- 
ual depression of the secretory response in control cells, pos- 
sibly due to depletion of readily releasable secretory granules 
[21,23,26]. The average values for three repetitive stimulations 
from 15 cells are shown in Fig. 1C. 
When noradrenaline (20 ~tM) was perfused on the cell prior 
to the second depolarizing step, a strong inhibition of exocy- 
tosis was observed in most of the cells (Fig. 1, Aii), even 
though inhibition of Io~ was small (Fig. 1, Bii) (see also [8]). 
The inhibition of exocytosis was rapidly reversed upon wash- 
out of noradrenaline, as seen from the recovery of ACm by the 
third depolarization (Fig. 1, Aii). The average values from 17 
noradrenaline-treated cellsis shown in Fig. 1D. The average 
ACre in response to the second step depolarization i  the pres- 
ence of noradrenaline was significantly smaller than the cor- 
responding ACre in control cells (P = 0.0003). Lack of a sta- 
tistical difference between the average ACre in response to the 
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Fig. 3. Noradrenaline inhibits both KC1- and ionomycin-stimulated 
[aH]5HT release from RINm5F cells. A: KCI (50 mM) induced 
[3H]5HT release from RINm5F cells (10 min of incubation at 37°C, 
n = 9). NA (10 [aM) inhibited KCl-induced secretion (  = 9). Pretreat- 
ment with PTX (200 ng/ml, 10 h, shaded bars) blocked the inhibi- 
tory action of NA (n= 3), without affecting KCl-induced [3H]5HT 
release (n=3). B: Ionomycin (1 txM)-induced [aH]5HT release 
(n= 5) was also blocked by NA (10 ~tM, n= 5). While ionomycin-in- 
duced [3H]5HT release was unaffected by PTX (n = 3), the NA inhi- 
bition was abolished by the PTX pretreatment (  = 3). 
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Fig. 2. Noradrenaline inhibits exocytosis by acting downstream 
from Ca 2+ entry and in a PTX-sensitive manner. A: Example of the 
inhibition by 20 ~tM NA of the ACre induced by 1 IxM ionomycin 
in an individual RINm5F cell held at -90 mV. Drug applications 
are indicated by horizontal bars. B: Pretreatment of RINm5F cells 
with 200 ng/ml PTX for 10 h blocked the inhibitory action of NA. 
C and D: The average rate of the ACre measured in individual cells 
by a linear fit to the Cm trace is plotted. In control cells, NA inhib- 
ited the increase in Cm induced by ionomycin (C, n =6). In cells 
pretreated with PTX, NA had no significant effect on average rates 
of secretion (D, n = 4). 
third step following noradrenaline washout (Fig. 1D), com- 
pared to the third response in control cells (Fig. 1C), con- 
firmed that recovery of exocytosis was complete. 
As shown in Fig. 1E, no correlation was found between the 
extent of Ica inhibition and the extent of ACre inhibition; an 
almost complete block of exocytosis was observed in some 
cells with very little Ic~ inhibition. In a few cells neither para- 
meter was affected by noradrenaline suggesting that in these 
cells the adrenergic receptors were absent, or their signalling 
deficient. 
To further test the hypothesis that the inhibitory action of 
noradrenaline on exocytosis from RINm5F cells was predo- 
minantly mediated by a direct inhibition of the secretory ap- 
paratus, the Ca 2+ ionophore ionomycin was used to stimulate 
secretion, thereby bypassing the contribution made by the 
adrenergic inhibition of the VOCCs [12]. Ionomycin (1 txM) 
produced a gradual increase in Cm which was completely 
abolished by co-perfusion with 20 txM noradrenaline (Fig. 
2A). When noradrenaline was removed, the ionomycin-in- 
duced increase in Cm resumed and reached rates that were 
not significantly different from the rates measured prior to 
noradrenaline application. The average rate of ACre due to 
ionomycin decreased significantly from 16.6+3.5 fF/s to 
-6.4+3.5 fF/s following noradrenaline application (n=6, 
P = 0.0005, Fig. 2C). The average negative slope of ACre in 
the presence of noradrenaline suggests that while exocytosis i
strongly inhibited, endocytosis remains functional in the pre- 
sence of the hormone. 
Both noradrenaline-induced I a inhibition [7,8] and the distal 
inhibition of insulin release from RINm5F cells [12] have been 
shown to be mediated by a PTX-sensitive G protein. To confirm 
this result at the single cell level, RINm5F cells were pretreated 
with 200 ng/ml PTX for 10 h. PTX pretreatment blocked the 
inhibitory action of 20 gM noradrenaline on ionomycin-stim- 
ulated exocytosis in all cells tested (Fig. 2B). The average rate 
of ACre in PTX pretreated cells was not significantly altered 
during the noradrenaline application (Fig. 2D, n = 4). 
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To confirm that the observed reductions in ACm caused by 
noradrenaline r flect inhibition of release (as opposed to a net 
increase in endocytosis), we examined the effects of noradre- 
naline on [3H]5HT release from RINm5F cell populations 
[25]. Like glucose-induced [3H]5HT release from mouse islets 
[27], KCl-evoked [3H]5HT release from RINm5F cells was 
also found to be strongly inhibited (89.8 + 1.2%, n = 9) by 10 
~M noradrenaline (Fig. 3A). To verify that the inhibition of 
[3H]5HT release is independent of the inhibition of the 
VOCCs, we also examined the effects of noradrenaline on 
ionomycin-induced [3H]5HT release. Ionomycin-stimulated 
release was similarly reduced (92.2+ 1.1%, n=5) by 10 ~tM 
noradrenaline (Fig. 3B). The similarity in the extent o which 
KCl-evoked and ionomycin-induced [3H]5HT release is inhib- 
ited by noradrenaline suggests that under these experimental 
conditions, VOCC inhibition plays a minor role in the actions 
of noradrenaline on hormone release from RINm5F cells. 
4. Discussion 
Noradrenaline, acting at c~2-adrenergic receptors, is a po- 
tent inhibitor of insulin release in vivo and in vitro [28]. Multi- 
ple targets of noradrenaline have been implicated in this in- 
hibitory action, including VOCC inhibition [7,8] and direct 
inhibitory effects on the secretory apparatus [9-12]. We have 
now combined voltage clamp and membrane capacitance de- 
tection techniques to simultaneously monitor the relative con- 
tribution of Ica inhibition, and direct effects on the secretory 
apparatus, to the noradrenergic nhibition of exocytosis in 
single RINm5F cells. 
Our results demonstrate that at the individual cell level, 
noradrenaline inhibits both VOCCs and secretion. This con- 
firms and extends previous observations on VOCC modula- 
tion [7,8] and on inhibition of insulin release made at the cell 
population level [9-12]. However, the extent o which exocy- 
tosis from individual RINm5F cells was inhibited by noradre- 
naline was found to be quite variable, and this variability did 
not correlate with the extent of Ic~ inhibition. A dissociation 
between adrenergic effects on secretion and either 45Ca2+ up- 
take from rat islets [9] or Quin2-detected Ca 2+ signals in 
RINm5F cells [10] has been previously reported. Still, these 
data were obtained on cell populations and VOCC modula- 
tion was not directly assayed. 
In RINm5F cells noradrenaline targets N-type VOCCs in a 
voltage-dependent manner and L-type VOCCs in a voltage- 
independent manner [8]. The remaining VOCCs (Q-like, [29]) 
are less sensitive to noradrenaline [8]. While the role of the Q- 
like VOCCs in the control of secretion from RINm5F cells is 
still unknown, both N- and L-type VOCCs have been shown 
to be involved in this process, the L-type being the more 
relevant [30,31]. The finding that noradrenaline has more po- 
tent actions on exocytosis than on Ica could be due to the fact 
that noradrenaline targets the few VOCCs 'crucially' involved 
in secretion, a role apparently played by L-type VOCC in 
both adrenal chromaffin [32] and pancreatic beta [33] cells. 
Although we cannot completely exclude this hypothesis, 
two lines of evidence suggest hat this explanation is unlikely. 
First, if the inhibition of Ic~ was causing the block of secre- 
tion, the extent o which Ic~ and ACre were inhibited would be 
expected to be correlated, and this was not the case. Second, 
noradrenaline was potent in inhibiting both the exocytosis 
stimulated by Ca 2+ influx through the VOCCs and that stim- 
ulated by ionomycin. From the above evidence we conclude 
that the direct inhibitory modulation of the secretory appara- 
tus plays a crucial role in noradrenaline inhibition of exocy- 
tosis from single RINm5F cells, in agreement with previous 
data obtained studying insulin release from permeabilized rat 
islets [11], permeabilized RINm5F cells [12], and the data 
presented here on [3H]5HT release from RINm5F cell popu- 
lations. Based on these data we cannot exclude the possibility 
that noradrenaline also targets the Ca 2+ handling capability 
of RINm5F cells; however, in the presence of ionomycin, 
which permits high sustained Ca 2+ levels to be reached in 
the cell cytoplasm, secretion is clearly inhibited by noradrena- 
line (see also [12]). 
These distal effects of noradrenaline are mediated by a 
PTX-sensitive G protein ([12] and this paper), but several 
PTX-sensitive G proteins are present in RINm5F cells [7]. 
Recent evidence obtained by Lang et al. [34] suggests that 
both Gi and Go can participate in these distal adrenergic 
effects on secretion in normal rat beta and HIT-T15 insulino- 
ma cells. However, a Gi-mediated inhibition of adenylate cy- 
clase seems not to be the mechanism by which noradrenaline 
inhibits secretion 'distally' from RINm5F cell populations 
[12]. 
The molecular targets of the 'distal', G protein-mediated 
effects of noradrenaline are still uncertain. A direct inhibitory 
action on the secretory apparatus, however, is emerging as a 
general mechanism by which hormones and neurotransmitters 
inhibit release from both nerve terminals [1,2,4-6] and neu- 
roendocrine cells [3,9-12]. Furthermore, there is evidence in 
both nerve terminals [2] and RINm5F cells [35] that not 
only the hormonal inhibition of release, but also its stimula- 
tion, could be achieved by the modulation of distal steps of 
the secretory process, downstream from second messenger 
production. We have recently found that while both exocyto- 
sis and endocytosis occur following Ca 2+ influx in RINm5F 
cells, substitution with Ba 2+ preferentially supports exocytosis 
[23], suggesting that the divalent ion sensitivities of the pro- 
teins involved in these two processes are different. Likewise, 
the observation at the single cell level that the adrenergic 
inhibition of exocytosis is not accompanied by an inhibition 
of endocytosis suggests that the proteins targeted by noradre- 
naline are specific to the exocytotic pathway. 
Acknowledgements: This work was supported by NIH Grant ROI 
NS-15453 and a grant from the Ida Russell Cades Fund to Ian M. 
Cooke, in whose laboratory part of the work was conducted. E. Sher 
was a fellow of the Telethon, Italia program. A. Codignola is a re- 
cipient of a fellowship from Associazione ltaliana per la Ricerca sul 
Cancro (AIRC). 
References 
[1] Man-Son-Hing, H., Zoran, M.J., Lukowiak, K. and Haydon, 
P.G. (1989) Nature 341,237 239. 
[2] Dale, N. and Kandel, E.R. (1990) J. Physiol. 421,203-222. 
[3] Luini, A. and De Matteis, M.A. (1990) J. Neurochem. 54, 30-38. 
[4] Scholz, K.P. and Miller, R.J. (1992) Neuron 8, 1139 1150. 
[5] Capogna, M., Gahwiler, B.H. and Thompson, S.M. (1993) 
J. Physiol. 470, 539-558. 
[6] Rekling, J.C. (1993) J. Neurosci. 13, 1954-1964. 
[7] Schmidt, A., Hescheler, J., Offermanns, S., Spicher, K., Hinsch, 
K.D., Klinz, F.J., Codina, J., Birnbaumer, L., Gausephol, H., 
Frank, R., Schultz, G. and Rosenthal, W. (1991) J. Biol. 
Chem. 266, 18025-18033. 
180 
[8] Polio, A., Lovallo, M., Biancardi, E., Sher, E., Socci, C. and 
Carbone, E. (1993) Pflugers Arch. 423, 462-471. 
[9] Morgan, N.G. and Montague, W. (1985) Biochem. J. 226, 571 
576. 
[10] Ullrich, S. and Wollheim, C.B. (1985) Mol. Pharmacol. 28, 100- 
106. 
[11] Jones, P.M., Fyles, J.M., Persaud, S.J. and Howell, S.L. (1987) 
FEBS Lett. 219, 139-144. 
[12] Ullrich, S. and Wollheim, C.B. (1988) J. Biol. Chem. 263, 8615- 
8620. 
[13] Neher, E. and Marty, A. (1982) Proc. Natl. Acad. Sci. USA 79, 
6712-6716. 
[14] Lim, N.F., Nowycky, M.C. and Bookman, R.J. (1990) Nature 
344, 449-451. 
[15] Thomas, P., Surprenant, A. and Almers, W. (1990) Neuron 5, 
723 733. 
[16] Neher, E. and Zucker, R.S. (1993) Neuron 10, 21-30. 
[17] von Riiden, L., Garcia, A.G. and L6pez, M.G. (1993) FEBS 
Lett. 336, 48-52. 
[18] von Gersdorff, H. and Matthews, G. (1994) Nature 367, 735-739. 
[19] Zorec, R., Sikdar, S.K. and Mason, W.T. (1991) J. Gen. Physiol. 
97, 473-497. 
[20] Gillis, K.D. and Misler, S. (1992) PfliJgers Arch. 420, 121-123. 
[21] Ammala, C., Eliasson, L., Bokvist, K., Larsson, O., Ashcroft, 
F.M. and Rorsman, P. (1993) J. Physiol. 472, 665-688. 
E. Sher et al./FEBS Letters 385 (1996) 176-180 
[22] Proks, P. and Ashcroft, F. (1995) J. Physiol. 487.2, 465-477. 
[23] Richmond, J.E., Codignola, A., Cooke, I.M. and Sher, E. (1996) 
Pflugers Arch. (in press). 
[24] Hamill, O.P., Many, A., Neher, E., Sakmann, B. and Sigworth, 
F.J. (1981) Pfltigers Arch. 391, 85-100. 
[25] Codignola, A., Tarroni, P., Clementi, F., Polio, A., Lovallo, M., 
Carbone, E. and Sher, E. (1993) J. Biol. Chem. 268, 26240- 
26247. 
[26] Augustine, G.J. and Neher, E. (1992) J. Physiol. 450, 247 271. 
[27] Gylfe, E. (1978) J. Endocr. 78, 239-248. 
[28] Miller, R.E. (1981) Endocr. Rev. 2, 471-494. 
[29] Magnelli, V., Polio, A., Sher, E. and Carbone, E. (1994) Pflfigers 
Arch. 429- 772-780. 
[30] Wollheim, C.B. and Pozzan, T. (1984) J. Biol. Chem. 259, 2262- 
2267. 
[31] Sher, E., Biancardi, E., Polio, A., Carbone, E., Li, G., Wollheim, 
C.B. and Clementi, F. (1992) Eur. J. Pharmacol. 216, 407-414. 
[32] Artalejo, C.R., Adams, M.E. and Fox, A.P. (1994) Nature 367, 
72-76. 
[33] Bokvist, K., Eliasson, L., Ammala, C., Renstr6m, E. and Rors- 
man, P. (1995) EMBO J. 14, 50-57. 
[34] Lang, J., Nishimoto, I., Okamoto, T., Regazzi, R., Kiraly, K., 
Weller, U. and Wollheim, C.B. (1995) EMBO J. 14, 3635-3644. 
[35] Tang, S.H., Yaney, G.C. and Sharp, W.G. (1995) Mol. Pharma- 
col. 47, 863 870. 
